Everest Clinical Research Buys Firma Clinical Research Data Unit

Key Takeaways

• The recently announced acquisition adds a biometrics team with experience across more than 1,000 clinical studies and over 60 NDA submissions.
• The deal expands global clinical data science capacity as sponsors increasingly outsource complex trial operations.
• Integration quality, regulatory consistency, and staff retention will shape how quickly the transaction benefits customers.

Everest Clinical Research, a data-focused contract research organization backed by Arlington Capital Partners, has acquired the Biometrics and Data Services business unit of Firma Clinical Research. The transaction adds a team that has supported more than 1,000 clinical studies and over 60 New Drug Application submissions across complex therapeutic areas.

That experience is central to the deal. Biometrics units typically bring together biostatistics, statistical programming, clinical data management, and related submission support. Those functions sit near the heart of a clinical development program, where data quality, traceability, and regulatory readiness can affect timelines long after patient enrollment has ended.

The acquisition expands the CRO's global biometrics and clinical data science capabilities rather than simply adding general clinical operations capacity. For pharmaceutical and biotechnology sponsors, the distinction matters. A CRO with deeper statistical and data management resources can potentially support programs from database design and cleaning through analysis, dataset preparation, and submission.

Clinical studies are producing more data from diverse sources. Electronic data capture systems, laboratories, imaging providers, wearable devices, electronic clinical outcome assessments, and decentralized trial technologies can all feed a single program. Because these streams arrive in different formats, on different schedules, and with uneven quality controls, sponsors increasingly look to specialized CROs to manage that complexity while maintaining a defensible audit trail.

Recent market estimates reinforce the commercial logic. The global healthcare contract research outsourcing market is projected to increase from $65.11 billion in 2025 to $71.97 billion in 2026 and $118.78 billion by 2031, representing a 10.54% compound annual growth rate. Coverage from Towards Healthcare also points to continued attention around U.S. clinical trial management services as drug developers seek outside operational and technology expertise.

Data-focused segments are expected to expand particularly quickly. The clinical trial data management service market is estimated at $1.1 billion in 2025 and forecast to reach $2.5 billion by 2035, representing an 8.3% compound annual growth rate. Separately, the broader clinical data management market is projected to rise from $3.63 billion in 2026 to $6.75 billion by 2031, at a 13.20% rate, with CROs forecast as the fastest-growing end-user segment. Market.us has likewise tracked growth in the clinical data management system market, reflecting wider demand for structured and submission-ready trial information.

Market consolidation is also a factor. The global clinical trials outsourcing market is projected to grow from $50.7 billion in 2024 to $101.9 billion by 2035 at a 6.4% compound annual rate. As that spending pool grows, CROs are under pressure to offer broader capabilities without losing specialist depth. Large competitors such as IQVIA and ICON have scale across multiple clinical development functions. The acquisition of Firma Clinical Research’s Biometrics and Data Services unit gives the company another route: expanding through a specialized team with an established study and submission record.

Still, buying expertise and integrating it are different challenges. Sponsors will likely watch whether Everest Clinical Research preserves continuity in project teams, statistical methods, programming environments, quality controls, and customer communication. Clinical data cannot simply be moved like a routine corporate workload. Changes need to account for Good Clinical Practice under ICH E6 as well as CDISC standards such as SDTM and ADaM, which structure datasets used in regulatory review.

The transaction could therefore be judged less by immediate scale than by execution. If the organization retains the acquired specialists and brings processes together without disrupting active programs, the purchase can broaden its role with existing sponsors and support larger, more data-intensive studies. If integration introduces delays or inconsistent workflows, customers will notice quickly. In biometrics, operational details tend to become strategic ones.